Badr El Khouzai

108 posts

Badr El Khouzai

Badr El Khouzai

@BElkhouzai

Radiation oncologist @UniPadova | #pcsm #hncsm #radonc

Katılım Mayıs 2019
302 Takip Edilen179 Takipçiler
Badr El Khouzai retweetledi
Chad Tang, MD
Chad Tang, MD@ChadTangMD·
Extremely excited to share our latest article published @TheLancetOncol a few hours ago: authors.elsevier.com/a/1mYT65EIIgTS…. The WOLVERINE individual patient meta-analysis was an international collaboration and part of X-MET collaboration. Goal was to evaluate MDT in oligomet prostate ca.
English
11
52
140
14.1K
Badr El Khouzai retweetledi
Adam B. Weiner, MD
Adam B. Weiner, MD@Adam_Weiner535·
🚨 New @TheLancet Seminar: #ProstateCancer🚨 Key takeaways ⬇️ 🧬 Biology & heterogeneity matter Prostate cancer isn’t one disease—molecular subtypes (eg, BRCA2, PTEN, AR alterations) increasingly guide therapy 🔍 Diagnosis has evolved MRI-first pathways + PSMA PET outperform conventional imaging, but raise questions about stage migration ⏸️ Active surveillance is standard Preferred for low-risk disease and select intermediate-risk pts—reduces overtreatment with excellent long-term outcomes 🏥 Local therapy ≈ equivalent cancer control Surgery, EBRT, brachytherapy all effective—decision hinges on toxicity profiles & patient preferences 🔥 High-risk disease = multimodal RT + long-term ADT ± ARPIs now core; surgery often part of a combined strategy 🌍 Metastatic landscape transformed ADT + ARPI (± docetaxel) improves OS; triplet therapy for fit, high-volume pts 🎯 Targeted & radioligand therapies PARP inhibitors (BRCA-driven benefit) and Lu-177–PSMA are reshaping mCRPC care 🤝 Shared decision-making is central Toxicity, quality of life, and sequencing remain key unanswered questions Essential read for anyone treating prostate cancer 👇 @PCF_Science @PCFnews @urotoday @UrologyTimes @Ecastromarcos @alison_tree 🔗shorturl.at/xZti6
Adam B. Weiner, MD tweet mediaAdam B. Weiner, MD tweet mediaAdam B. Weiner, MD tweet media
English
0
28
92
7.9K
Badr El Khouzai retweetledi
Pierre Blanchard, MD
Pierre Blanchard, MD@PBlanchardMD·
@h_mehanna @H_N_C_I_G presents results of CompARE trial at #ESMO26 on the use of induction and adjuvant durvalumab to concurrent CRT for oropharyngeal cancer. No benefit overall in DFS or OS. possible benefit in high risk patients. No added toxicity.
Pierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet media
English
2
4
9
350
Badr El Khouzai retweetledi
Pierre Blanchard, MD
Pierre Blanchard, MD@PBlanchardMD·
STOPCAP at #ESMO26 Benefit of #radiotherapy in de novo M1 #prostatecancer on OS & PFS. Restricted to <5 bone or low volume mets on conventional imaging. No interaction with other patient/tumor characteristics.
Pierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet media
English
3
52
110
4.8K
Badr El Khouzai retweetledi
Dr Rishabh Jain
Dr Rishabh Jain@DrRishabhOnco·
🧬 Cribriform architecture changes the story in localized prostate cancer. 🔥 ProtecT 15-year biopsy re-review shows who really needs treatment vs surveillance. 🎯 n = 712 with available slides (13 % cribriform+) 💊 Arms: ▫️ Active monitoring ▫️ Radical prostatectomy ▫️ Radiotherapy + neoadjuvant ADT 📊 Key Results • Cribriform + → ↑ metastasis risk (HR 3.61, 95 % CI 1.60-8.11) • RT + ADT → lowest metastasis (HR 0.35 vs active monitoring) • Surgery → HR 0.52 vs active monitoring (NS) • 15-yr metastasis (cribriform +): AM 25 % | Surg 26 % | RT + ADT 8 % • Cribriform –: 7 % | 4 % | 3 % ✅ Takeaway: Cribriform + = treat aggressively (RT + ADT best long-term control) Cribriform – = active surveillance still safe for most patients. 📖 Sushentsev et al. JAMA Oncology 2025. 🔗 doi.org/10.1001/jamaon… #OncoTwitter #MedTwitter #ProstateCancer #UroOnc @OncoAlert @myesmo @esmo_open @ASCO @JAMAOnc
Dr Rishabh Jain tweet media
English
2
75
168
16K
Badr El Khouzai retweetledi
Pierre Blanchard, MD
Pierre Blanchard, MD@PBlanchardMD·
De escalated therapy is safe for stage IIA-IIB seminoma! ✅No recurrence since initial presentation in 2021. ✅No severe toxicity. ✅Secondary malignancies only outside of radiotherapy fields. Long term outcomes of SAKK 01/10 by @Alex_Papachris at #ESMO2
Pierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet media
English
2
46
96
4.2K
Badr El Khouzai retweetledi
Tony Felefly
Tony Felefly@TonyFelefly·
The RAMPP trial has landed ‼️ Congratulations to the authors for this great work!! It compared best systemic therapy + RP (with extended LND) to BST alone for patients with de-novo synchronous oligometastatic PCa, defined as =< 5 bone mets. BST consisted of lifelong ADT. It closed early due to STAMPEDE results. Cancer-Specific mortality was the primary enpoint. Clinical progression and OS were secondary endpoints. An X-torial 1/n @euplatinum @urotoday @dr_coops @chapinmd @pcaparker @soum_roy_radonc @drspratticus @drandrewloblaw @tylersbrt @seanmmcbride @sbrtsean @alison_tree @vedangmurthy @piet_ost @paulsargos @jryckman3 @5_utr @protonstorey @docpriyamvada @_shankarsiva @alexsherrymd @albertobossial @xristodouleas @amarukishan @zklaassen_md @themednet #OncoTwitter #ProstateCancer #RadOnc #UroOnc @oncoalert #s0075" target="_blank" rel="nofollow noopener">sciencedirect.com/science/articl…
English
7
19
46
20.3K
Badr El Khouzai retweetledi
Pierre Blanchard, MD
Pierre Blanchard, MD@PBlanchardMD·
SBRT (6*6Gy) is a new treatment option for small oral cavity cancers (T1-2) at risk of local recurrence after resection (R1, PNI..): Julian Biau reports the STEREOPOSTOP GORTEC 2017-03. Convenient Fast Similar outcomes than post op brachy Mostly VMAT homogeneous plans #ESTRO25
Pierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet media
English
9
56
139
12.1K
Badr El Khouzai retweetledi
Gustavo
Gustavo@gusviani·
Timing matters? ⏰ Morning ☢️⬆️ survival in NPC without added toxicity. Should we rethink RT scheduling? 🤔@OncoAlert 🎯Objective: •Investigate the impact of ☢️ timing (morning, afternoon, night) on OS and toxicity in NPC 🔬Methods: •Retrospective analysis of 1,040 NPC 👥 treated w/ IMRT •👥 grouped by treatment ⌚: Morning (6:00-11:59), Afternoon (12:00-17:59), Night (18:00-24:00) •PSM and Cox used to ⚖️ confounders 📊Results: •Morning RT ⬆️ OS •HR: Afternoon (5.88, P=.004), Night (4.81, P=.018)😱 •N🚫 difference in acute toxicity between groups 🗣Conclusion: Morning ☢️ ⬆️survival for NPC. Prospective studies are needed to confirm findings❗️
Gustavo tweet mediaGustavo tweet mediaGustavo tweet media
English
9
21
76
9.7K
Badr El Khouzai retweetledi
David Sher
David Sher@DavidSherMD·
Excited to see HN004 out in publication! In Star Wars terms, if HN005 is Seventy Gray Strikes Back, then HN004 is The Rise of Cetuximab thelancet.com/journals/lanon…
English
1
15
51
4.7K